Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.44 |
| ▸ | CKS1B | P61024 | 2/20 | 0.38 |
| ▸ | SKP1 | P63208 | 2/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | HPGDS | O60760 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5518832 | 0.88 | USP30 (0.41) | USP30CKS1BSKP1SKP2PDE10A | |
| SCHEMBL5509582 | 0.84 | USP30 (0.41) | USP30CKS1BSKP1SKP2PDE10A | |
| SCHEMBL5507973 | 0.81 | USP30 (0.40) | USP30CKS1BSKP1SKP2PDE10A | |
| SCHEMBL5507958 | 0.80 | PDE10A (0.38) | USP30CKS1BSKP1SKP2PDE10A | |
| SCHEMBL5509641 | 0.78 | KDM4E (0.37) | USP30CKS1BSKP1SKP2PDE10A | |
| SCHEMBL16392572 | 0.76 | PIK3CD (0.52) | USP30PDE10APIK3CDHPGDS | |
| SCHEMBL4545723 | 0.76 | PIK3CD (0.52) | USP30PDE10APIK3CDHPGDS | |
| SCHEMBL5996420 | 0.75 | MEN1 (0.40) | KDM4EALDH1A1SMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL5510597 | 0.72 | UCHL1 (0.49) | USP30PDE10AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4402616 | 0.71 | PDE10A (0.61) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838702-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | Pfizer Products Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060183763-A1 | Novel pyrrolidyl derivatives of heteroaromatic compounds | PFIZER INC | 2006-08-17 | — | — | US | disclosed |
| WO-2006070284-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006070284-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183763-A1 | Novel pyrrolidyl derivatives of heteroaromatic compounds | PDE12, PDE4A, PDE7A | USP30 534/4885CKS1B 1196/4885SKP1 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.